UnitedHealth Group (UNH)
(Delayed Data from NYSE)
$566.03 USD
-5.31 (-0.93%)
Updated Oct 17, 2024 04:00 PM ET
Pre-Market: $562.59 -3.44 (-0.61%) 8:24 AM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$566.03 USD
-5.31 (-0.93%)
Updated Oct 17, 2024 04:00 PM ET
Pre-Market: $562.59 -3.44 (-0.61%) 8:24 AM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Zacks News
Wall Street Analysts Think UnitedHealth (UNH) Is a Good Investment: Is It?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), UnitedHealth (UNH) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Stock Market News for Jul 17, 2023
by Zacks Equity Research
U.S. stock markets closed mixed on Friday following mixed earnings results of second-quarter 2023.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
UnitedHealth Group (UNH) Q2 Earnings Beat, Boosts '23 EPS View
by Zacks Equity Research
UnitedHealth Group's (UNH) Q2 results benefited on the back of solid contributions from the UnitedHealthcare and Optum segments. Management presently forecasts adjusted net EPS within $24.70-$25.00 for 2023.
Wall Street Kicks Off Q2 2023 Earnings Season
by Zacks Equity Research
Wall Street Kicks Off Q2 2023 Earnings Season
JPMorgan Posts +20% Beat; C, WFC, UNH Also Outperform
by Mark Vickery
Earnings of $4.37 per share easily outpaced the $3.62 in the Zacks consensus and the $2.76 per share reported a year ago.
UnitedHealth (UNH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for UnitedHealth (UNH) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
UnitedHealth Group (UNH) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
UnitedHealth (UNH) delivered earnings and revenue surprises of 3.72% and 2.54%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Visa, UnitedHealth Group, Eli Lilly, Costco, Wholesale and Advanced Micro Devices
by Zacks Equity Research
Visa, UnitedHealth Group, Eli Lilly, Costco, Wholesale and Advanced Micro Devices are part of the Zacks top Analyst Blog .
Top Analyst Reports for Visa, UnitedHealth & Eli Lilly
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), UnitedHealth Group Incorporated (UNH) and Eli Lilly and Company (LLY).
Will UnitedHealth's (UNH) UnitedHealthcare Unit Aid Q2 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) second-quarter results are expected to benefit from an increase in UnitedHealthcare's Community & State revenues, as well as the number of people served.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Will High Medical Costs Affect UnitedHealth (UNH) Q2 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) second-quarter results are likely to reflect growth in memberships and expense levels.
Factors That Make Universal Health (UHS) an Attractive Bet Now
by Zacks Equity Research
Universal Health (UHS) remains well-poised for growth on the resumption of elective surgeries, a diversified treatment network and solid cash reserves.
UnitedHealth Group (UNH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
UnitedHealth (UNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UnitedHealth's (UNH) Suffering Continues: Should You Hold Tight?
by Zacks Equity Research
Each sub-segment of Optum, UnitedHealth's (UNH) health service business, is expected to continue delivering a solid performance, driving the overall segment's growth.
UnitedHealth Group (UNH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
UnitedHealth Group (UNH) closed at $477.88 in the latest trading session, marking a -0.57% move from the prior day.
These 3 Companies Are Cash-Generating Machines
by Derek Lewis
A company displaying free cash flow strength has freedom for growth opportunities, can consistently shell out dividends, and wipe out debt easily.
UnitedHealth Group (UNH) Gains But Lags Market: What You Should Know
by Zacks Equity Research
UnitedHealth Group (UNH) closed the most recent trading day at $482.56, moving +0.73% from the previous trading session.
Factors That Make HCA Healthcare (HCA) a Lucrative Bet Now
by Zacks Equity Research
HCA Healthcare (HCA) remains well-poised for growth on the resumption of elective surgeries, acquisitions and strong cash-generation abilities.
UnitedHealth Group (UNH) Expands Home Healthcare Business
by Zacks Equity Research
UnitedHealth Group (UNH) boosts home healthcare presence with the acquisition of Amedisys for $3.3 billion
UnitedHealth Group Incorporated (UNH) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
UnitedHealth (UNH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
UnitedHealth's (UNH) Optum Rx Makes Patient Care Affordable
by Zacks Equity Research
UnitedHealth Group, Inc's. (UNH) Optum Rx is set to offer three biosimilar alternatives for HUMIRA effective Jul 1, providing affordability in patient care.
UnitedHealth Group (UNH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, UnitedHealth Group (UNH) closed at $476.75, marking a +1.57% move from the previous day.